Eli Lilly and Novo Nordisk agreed to discount their GLP-1 medications from $1350 per month to around $245 to $350 per month.

After writing dozens of GLP-1 articles over the past year, one issue that consistently comes up is the affordability of ...

There’s a reason why millions of people in the UK are on weight-loss injections – and it’s not because we’re all weak, writes ...

This article was reviewed by Darragh O’Carroll, MD. Semaglutide Side Effects: What to Know Key takeaways: Common semaglutide ...

Below, doctors explain everything you need to know about the phenomenon. It’s important to be clear upfront that “Ozempic ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s ...

Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking ...